Azienda Unita Sanitaria Locale Di Bologna
- Address
- lock Available on a paid plan
Neuro-oncology and Neoplasms
At Azienda Unita Sanitaria Locale Di Bologna, the neurology team is involved in clinical research on H3 K27M-mutant diffuse glioma, focusing on brain tumors within the broader field of neoplasms. These studies are designed to assess whether new treatment approaches can improve outcomes after standard care and support better disease control.
- Evaluating a new therapy for H3 K27M-mutant diffuse glioma after radiotherapy
- Studying treatment effectiveness in a rare and aggressive brain tumor
- Advancing care in neuro-oncology through targeted research
This work reflects a strong interest in improving options for patients with difficult-to-treat central nervous system cancers.
Stroke prevention and Cardiovascular Diseases
Clinical trials at this site also address ischemic stroke prevention, including patients recovering from an acute non-cardioembolic stroke or those at high risk after a transient ischemic attack. Research in this cardiovascular area is aimed at reducing the chance of another stroke while also assessing safety and overall treatment benefit.
- Preventing recurrent ischemic stroke after a recent event
- Evaluating whether a new oral treatment can improve protection beyond standard antiplatelet therapy
- Monitoring safety outcomes, including major bleeding risk
These studies support better long-term management of patients with high vascular risk and a history of stroke-related events.
Huntington’s disease and Congenital, Hereditary, and Neonatal Diseases and Abnormalities
The research portfolio at Azienda Unita Sanitaria Locale Di Bologna includes studies in Huntington’s disease, a progressive inherited neurological disorder. The trials are exploring both long-term safety and biological effects of a potential therapy, with the goal of better understanding how to slow or modify the disease process.
- Assessing the long-term safety of an investigational treatment for Huntington’s disease
- Measuring changes in disease-related biomarkers linked to huntingtin levels
- Supporting research into inherited neurological disorders
This area of research is especially important for families affected by rare genetic conditions, where new therapeutic options are still urgently needed.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 18 therapeutic areas and 15 of 107 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 99 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +13 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Sanitaria Locale Di Bologna
lock Showing 1 of 91 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study | Fondazione IRCCS Policlinico San Matteo | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 107 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 3 | Unknown | 2021-10-13 | 2023-01-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.